CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2013—Skuldtech, a genomic biomarker company, has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer disease that has received funding of EUR 8.6 million in total. The program is scheduled to last four years, with the first results expected in 2018.
Read More »